All News

Torgashina et al Rituximab in Sjogrens ILD. ILD first manifestation of Sjogrens in 26%. Rituximab improvement in 37% and stabilisation in 47%. @RheumNow #EULAR2022 POS0710 https://t.co/CCnPVrTGfI
Richard Conway RichardPAConway ( View Tweet)
#EULAR2022 OP0278: Increase in risk of CVA compared to general population ~1.2x risk ⭐️This is unchanged between the pre-biologic (1972-1998) and the post-biologic treatment era ⭐️Interesting finding: smoking rate same over time in RA, despite decr in Norway in gen pop @Rheumnow https://t.co/r8QsJABfvx
Eric Dein ericdeinmd ( View Tweet)
Charles-Schoeman et al. ORAL Surveillance. PE risk factors - History VTE, antidepressant use, obesity, steroids, male, age, OCP/HRT. PPI protective @RheumNow #EULAR2022 POS0239 https://t.co/fDLKrpvpgI
Richard Conway RichardPAConway ( View Tweet)
Pan et al. SPI-62 (11beta-hydroxysteroid dehydrogenase inhibitor) minimises steroid side effects in animal studies. Now going on to a clinical trial in PMR. Exciting as steroid adverse events are a huge problem in PMR/GCA @RheumNow #EULAR2022 POS1332 https://t.co/NEoIx971jS
Richard Conway RichardPAConway ( View Tweet)
Can we predict VTEs from JAKi for RA at all? Baseline elevated D-dimer pts who go on to develop VTE (but not baseline CRP, so not just general inflamm) Questions raised about effect modification for VTE following JAKi too. This story not yet done OP0269 #EULAR2022 @RheumNow https://t.co/ErDcFpXXUl
David Liew drdavidliew ( View Tweet)
#EULAR2022 OP0277 MSK IRAE from Checkpoint inhibitors ⭐️118 pts w MSK complaints 76% w arthralgias/myalgias, 30% with inflammatory rheumatic features Most grade 1/2, 2 grade 4 (myositis) 23 (19.5%) required d/c, time of resolution ~3 mos, 20% persistence at end of study @RheumNow https://t.co/SINqmmjsLq
Eric Dein ericdeinmd ( View Tweet)
Leng et al. Tocilizumab biosimilar BAT1806/BIIB800 vs originator in MTX-IR RA. Not surprisingly they look the same. Great to see given negative clinical impact of recent supply problems with originator. @RheumNow #EULAR2022 POS0287 https://t.co/EqwINwcm7M
Richard Conway RichardPAConway ( View Tweet)
Tomelleri @tomelleri_a et al. GCA. Tocilizumab weekly x 1 year, then every other week x 1 year, then stop. 2 PMR flares during toc. 1 month post-stop 100% remission. 6 months post-stop 24% GCA flare! Some patients seem to need indefinite toc @RheumNow #EULAR2022 POS0266 https://t.co/8I5GQ08HDr
Richard Conway RichardPAConway ( View Tweet)
Long-term low-dose steroids for RA: can it be weaned? Weaning after 2y of blinded add-on in RA: either PNL 5mg/d or placebo No substantial evidence of adrenal insufficiency - symptoms same - cortisol/ACTH same It's never too late to wean the pred! OP0270 #EULAR2022 @RheumNow https://t.co/jp2ZOlAEnb
David Liew drdavidliew ( View Tweet)
🧫 JAKi and NK cells activation: JAKi and particularly TOFA impacts NK cells: *phenotype *function *impairs the control of proliferation of lung cancer and lymphoma cell lines An explanation for the increase of cancer events in ORAL surveillance? @RheumNow #EULAR2022 OP0265 https://t.co/LzMLdzcsDU
Aurelie Najm AurelieRheumo ( View Tweet)
MACE events no diff in German RA Rabbit registry of only humans shows #baricitinib and #tofacitinib vs #TNFis @RheumNow @eular_org #EULAR2022 OP0135 https://t.co/O8iOA7jpal

Links:

Janet Pope Janetbirdope ( View Tweet)

#EULAR2022 OP0274 Hospitalization for TB and other opportunistic infxn (OI) w inflamm joint disease: ⭐️9% with RA, 6% with PsA and AS in Western Australia ⭐️Decrease overall since 1985, but recent increase ⭐️Sharp rise of mycotic infections ⭐️No PJP, likely due to ppx @Rheumnow

Eric Dein ericdeinmd ( View Tweet)

Low socioeconomic status should on the list as a high risk factor (#notJUSTrace) https://t.co/zikGGLISSN

Links:

TheDaoIndex KDAO2011 ( View Tweet)

Yoshimura et al. 10 year findings of TOMORROW study. Glucocorticoid use of even 2mg/day is fracture risk in RA! @RheumNow #EULAR2022 POS0631 https://t.co/c8uCdPzUiE
Richard Conway RichardPAConway ( View Tweet)
Visual symptoms in GCA: should we take it on face value? @cmukhtyar group tertiary rheum/ophthal n=350 consecutive GCA pts diagnosed (bx/PET) visual symptoms 29% ocular signs 13% Not all symptoms = signs No doubt not all symptoms of same concern POS0810 #EULAR2022 @RheumNow https://t.co/TYHylpBhkN
David Liew drdavidliew ( View Tweet)
@Yuz6Yusof on breakthrough infections & severe #COVID in RTX treatment #EULAR2022 🦠Rate of mod/severe COVID infection comparable to pre-pandemic severe infection rate 💉High vaccination rate prevented severe disease 📊Consider #comorbidities & low IgG in risk-benefit assessment https://t.co/PGUVbHD7i2
Mrinalini Dey DrMiniDey ( View Tweet)
BE COMPLETE RCT Bimekizumab vs. PBO in TNFiIR PsA pts meets its primary criteria at 16wks w/ -ACR50 43% -PASI 90 69% and MDA achieved in 40+% pts No new safety signal. @RheumNow #EULAR2022 OP0255 https://t.co/QazYlzDqIc
Aurelie Najm AurelieRheumo ( View Tweet)
Study of 184 #SLE pts shows that major infections in SLE results in a 7 fold increased risk of a major lupus flare. Abst# OP0143 #EULAR2022 https://t.co/yMJcMAFSh6
Dr. John Cush RheumNow ( View Tweet)
RA & dementia - it's getting more damning RA dementia risk: HR 1.25 from Korean nationwide data: RA n=138,592 this follows @MyasoedovaElena's data RA systemic inflamm leading to dementia (AD, vascular)? Need to understand if any DMARD protective OP0271 #EULAR2022 @RheumNow https://t.co/4V7fOtVlnj
David Liew drdavidliew ( View Tweet)
Merola et al. IL23i Risankizumab in PsA. Proportion achieving ACR20 week24 by subgroup. Effective across all groups. Similar irrespective of demographics, disease characteristics, concomittent meds, prior bDMARD use. @RheumNow #EULAR2022 POS1032 https://t.co/GAVKFpwCst
Richard Conway RichardPAConway ( View Tweet)
×